{"nctId":"NCT00036270","briefTitle":"Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane","startDateStruct":{"date":"2001-08"},"conditions":["Breast Neoplasms"],"count":9779,"armGroups":[{"label":"exemestane","type":"EXPERIMENTAL","interventionNames":["Drug: exemestane (Aromasin)"]},{"label":"tamoxifen + exemestane","type":"EXPERIMENTAL","interventionNames":["Drug: tamoxifen + exemestane"]}],"interventions":[{"name":"exemestane (Aromasin)","otherNames":["aromasin"]},{"name":"tamoxifen + exemestane","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically/cytologically confirmed adenocarcinoma of the breast, followed by adequate surgical resection and/or radiotherapy, and/or adjuvant chemotherapy, if indicated.\n* Stage T1-3 N0-2 Mo, Any TNM stage BC for whom adjuvant hormonal therapy is being considered.\n\nExclusion Criteria:\n\n* Those patients not deemed to have had potentially curative primary surgical treatment or one of the following criteria:\n* Inflammatory breast cancer\n* Histologically positive supraclavicular nodes\n* Ulceration/infiltration of local skin metastasis\n* Neoadjuvant chemotherapy\n* Ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS) without invasion\n* ER and PR negative primary tumor or ER/PR unknown status.","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Disease Free Survival (DFS): Number of Events (Disease Relapse or Death) From Baseline up to 2.75 Years","description":"Number of events (disease relapse or death) to time of observation for DFS. DFS defined as time from randomization to earliest documentation of disease relapse or death from any cause in postmenopausal, receptor positive, node negative or node positive breast cancer patients for adjuvant treatment with exemestane compared with adjuvant tamoxifen therapy at 2.75 years. Disease relapse: primary tumor recurrence (locoregional or distant) and ipsilateral or contralateral breast cancer (CBC). Intercurrent death: death without disease relapse.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"352","spread":null},{"groupId":"OG001","value":"388","spread":null}]}]}]},{"type":"PRIMARY","title":"Disease Free Survival (DFS): Number of Events (Disease Relapse or Death) From Baseline up to 5 Years","description":"Number of events (disease relapse or death) to time of observation for DFS. DFS defined as time from randomization to earliest documentation of disease relapse or death from any cause in postmenopausal, receptor positive, node negative or node positive breast cancer patients for adjuvant treatment with exemestane compared with adjuvant tamoxifen therapy at 5 years. Disease relapse: primary tumor recurrence (locoregional or distant) and ipsilateral or contralateral breast cancer (CBC). Intercurrent death: death without disease relapse.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"712","spread":null},{"groupId":"OG001","value":"714","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Events for Overall Survival (OS)","description":"Number of events (death) to time of observation for OS. OS is the duration from randomization to death. For participants who are alive, overall survival is censored at the last contact.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"485","spread":null},{"groupId":"OG001","value":"476","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to New Primary Breast Cancers","description":"New primary breast cancers were defined as events of ipsilateral/contralateral breast cancer (CBC).","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Number of Events for Time to Relapse","description":"Number of events to time of observation for relapse. Relapse is defined as all recurrences of the primary tumor (loco-regional and distant recurrence), second primary breast cancer, contralateral breast cancer.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"499","spread":null},{"groupId":"OG001","value":"521","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With New Primary Non-breast Cancers","description":"Number of participants with new primary non-breast cancers which included colorectal cancer, lung cancer, endometrial cancer, ductal carcinoma in situ (DCIS) and other primary cancer types.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"110","spread":null},{"groupId":"OG001","value":"106","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":784,"n":4814},"commonTop":["Hot flush","Arthralgia","Fatigue","Pain","Insomnia"]}}}